Find Gabexato manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 39492-01-8, Gabexate [inn], Ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate, Chembl87563, Ethyl p-hydroxybenzoate 6-guanidinohexanoate, Gabexate (inn)
Molecular Formula
C16H23N3O4
Molecular Weight
321.37  g/mol
InChI Key
YKGYIDJEEQRWQH-UHFFFAOYSA-N
FDA UNII
4V7M9137X9

Gabexato
A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
1 2D Structure

Gabexato

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate
2.1.2 InChI
InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)
2.1.3 InChI Key
YKGYIDJEEQRWQH-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N
2.2 Other Identifiers
2.2.1 UNII
4V7M9137X9
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Foy

2. Gabexate Mesilate

3. Gabexate Mesylate

4. Gabexate Methanesulfonate

5. Gabexate Monomethanesulfonate

6. Gabexate Monomethanesulfonate, 14c Labeled Cpd

7. Gabexate Monomethanesulfonate, 14c-labeled Cpd

8. Mesilate, Gabexate

9. Mesylate, Gabexate

10. Methanesulfonate, Gabexate

11. Monomethanesulfonate, Gabexate

2.3.2 Depositor-Supplied Synonyms

1. 39492-01-8

2. Gabexate [inn]

3. Ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate

4. Chembl87563

5. Ethyl P-hydroxybenzoate 6-guanidinohexanoate

6. Gabexate (inn)

7. 4v7m9137x9

8. Gabexato

9. Gabexatum

10. Gabexatum [inn-latin]

11. Gabexato [inn-spanish]

12. Methanesulfonic Acid Ethyl 4-[(6-carbamimidamidohexanoyl)oxy]benzoate

13. Unii-4v7m9137x9

14. Gabexate [jan]

15. Gabexate [mi]

16. Prestwick0_001008

17. Prestwick1_001008

18. Prestwick2_001008

19. Prestwick3_001008

20. Gabexate [who-dd]

21. Benzoic Acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, Ethyl Ester

22. Bspbio_001135

23. Schembl446024

24. Spbio_003016

25. Bpbio1_001249

26. Gtpl7863

27. Dtxsid9048566

28. Schembl13287301

29. Chebi:93036

30. Zinc2002226

31. Bdbm50104435

32. Db12831

33. Ethyl 4-(6-guanidinohexanoyloxy)benzoate

34. Ncgc00025297-01

35. Ncgc00025297-02

36. Ncgc00025297-10

37. Ls-14525

38. Sbi-0207080.p001

39. Ethyl 4-((6-guanidinohexanoyl)oxy)benzoate

40. Ethyl-p-(6-guanidinohex-anoyloxy)-benzoate

41. Ab00513998

42. D08004

43. Ab00513998_02

44. Q5515384

45. 4-(6-guanidino-hexanoyloxy)-benzoic Acid Ethyl Ester

46. Brd-k59256312-066-03-3

47. Ethyl 4-({6-[(diaminomethylidene)amino]hexanoyl}oxy)benzoate

48. 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic Acid Ethyl Ester

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 321.37 g/mol
Molecular Formula C16H23N3O4
XLogP31.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count11
Exact Mass321.16885622 g/mol
Monoisotopic Mass321.16885622 g/mol
Topological Polar Surface Area117 Ų
Heavy Atom Count23
Formal Charge0
Complexity400
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

No approved indication.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Gabexate bind and inhibits serine proteases in the coagulation cascade to prevent blood clotting. It also prevents proteolytic destruction of IkappaB resulting in suppression of the nuclear factor kappa-B signalling pathway. Ultimately this decreases the production of inflammatory cytokines such as tumor necrosis factor alpha which are produced as a result of NFkappaB activation.


5.2 MeSH Pharmacological Classification

Anticoagulants

Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)


Serine Proteinase Inhibitors

Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)


5.3 Mechanism of Action

Gabexate inhibits kallikrein, plasmin, and thrombin by binding to their active sites. The inhibition of these components of the coagulation cascade ultimately prevents the formation of fibrin which must be present and polymerized to form a clot. Gabexate decreases the production of inflammatory cytokines by attenuating NFkappaB and c-Jun N-terminal kinase (JNK) pathway activity. The exact mechanism for this is unknown but it is thought that gabexate prevents the proteolyytic destruction of IkappaB which deactivates NFkappaB and interferes with activator protein 1 binding to DNA.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty